Resultado de búsqueda
30 de may. de 2024 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC).
- Press Releases | Gilead
January 23, 2024. Gilead Sciences to Release Fourth Quarter...
- Gilead and Arcus Announce Etrumadenant Plus Zimberelimab ...
ARC-9 (NCT04660812) is a Phase 1b/2 trial evaluating the...
- Stories @ Gilead
How Luciana Preger is Helping Advance Gilead’s Work in...
- Gilead Statement on Agreement in Principle to Resolve Federal ...
Foster City, Calif., June 4, 2024 – Gilead Sciences has...
- Press Releases | Gilead
31 de may. de 2024 · Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA. June 05, 2024. Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis. June 04, 2024.
Hace 6 días · FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine receptor antagonist, plus anti-PD-1 monoclonal antibody zimberelimab, FOLFOX chemotherapy and bevacizumab (EZFB) in ...
28 de may. de 2024 · Kite Pharma (Gilead), una compañía que alcanza una tasa de éxito del 96% en la fabricación de terapias CAR-T. En la actualidad llega a más de 21.300 pacientes en todo el mundo a través de ensayos clínicos y de sus productos comercializados
Hace 4 días · Foster City, Calif., June 4, 2024 – Gilead Sciences has reached an agreement in principle with counsel representing the overwhelming majority of plaintiffs in the federal TDF litigation pending in the U.S. District Court for the Northern District of California (ADRIAN HOLLEY, et al.).
29 de may. de 2024 · How Luciana Preger is Helping Advance Gilead’s Work in Oncology. Gilead’s growing oncology portfolio and its efforts to ensure access to treatment are helping transform cancer care.
Hace 1 día · DEJA TU HUELLA, EL PROGRAMA DE SEMES CON LA COLABORACIÓN DE GILEAD . Por otro lado, en el campo de las enfermedades infecciosas, la actividad en este Congreso de #SEMES24 está siendo muy extensa.
